Atossa Therapeutics ATOS 深 沪
已收盘 09-11 16:00:00 美东时间
2.51
+0.170
+7.26%
华盛通- 最 高2.54
- 今 开2.36
- 成交量 6.04万股
- 最 低 2.36
- 昨 收 2.34
- 总市值 2504.80万
- 52周最高 19.35
- 市盈率 静 --
- 换手率 0.61%
- 52周最低 1.70
- 委 比 -85.36%
- 总股本 997.93万
- 历史最高 33480.00
- 量 比 1.52
- 振 幅 7.69%
- 历史最低 2.36
- 每 手 1
- 风险率 4.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Atossa Therapeutics Q2 EPS $(0.95) Beats $(1.02) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.02) by 6.86 percent. This is a 171.43 percent decrease over losses of $(0.35) per share from the same period last year.
08-07 21:30
Atossa Therapeutics Announces npj Breast Cancer Publication Highlighting Novel Endoxifen-Based Compounds In ESR1-Mutant Breast Cancer Models
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models Findings suggest potential for combination with abemaciclib SEATTLE, July 28, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), ...
07-28 20:35
Atossa公布罕见病McCune-Albright综合征新数据
Atossa Therapeutics（纳斯达克代码：ATOS）在近日举行的美国癌症研究协会（AACR）罕见癌症特别会议上，以壁报形式公布了其在研药物（Z...
07-21 22:41
Atossa Therapeutics Presents Mechanism-Driven (Z)-Endoxifen Data In McCune-Albright Syndrome At 2026 AACR Special Conference In Cancer Research
Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome SEATTLE, July 21, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clini...
07-21 20:34
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Price Target of $12.
07-08 00:49
Atossa Therapeutics Announces Registered Direct Offering and Warrants
Atossa Therapeutics ( ($ATOS) ) just unveiled an announcement. On June 10, 2026...
06-11 20:41
Atossa Therapeutics Enters Securities Purchase Agreement With Institutional Investors For 1,363,638 Shares
Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that it has entered into a securities purchase agreement with institutional investors fo...
06-11 20:18
Atossa Therapeutics在ASCO 2026公布(Z)-Endoxifen积极数据，展现克服ESR1突变潜力
临床阶段生物制药公司Atossa Therapeutics， Inc．（纳斯达克代码：ATOS）今日宣布，两篇关于其在研药物（Z）-Endoxifen的摘要...
05-28 03:13
Atossa Therapeutics Announces Acceptance Of (Z)-Endoxifen DMD Manuscript For Publication In Degenerative Neurological And Neuromuscular Disease
Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) researchSEATTLE, May 20, 2026 /PRNewswire/ --
05-21 04:49
